Colonization by pneumocystis jirovecii and its role in disease

Clinical Microbiology Reviews

Volumn 25, Issue 2, 2012, Pages 297-317

  Morris, Alison ^a   Norris, Karen A ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATOVAQUONE; CLINDAMYCIN; COTRIMOXAZOLE; DAPSONE; DIHYDROPTEROATE SYNTHASE; FIBRONECTIN; GAMMA INTERFERON; IMMUNOGLOBULIN G; INFLIXIMAB; KEXIN; LACTATE DEHYDROGENASE; PENTAMIDINE; PREDNISONE; PRIMAQUINE; RIBOSOME RNA; S ADENOSYLMETHIONINE; SULFAMETHOXAZOLE; TRIMETHOPRIM; VITRONECTIN;

ADJUVANT THERAPY; ADRENAL DISEASE; AUTOIMMUNE DISEASE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COUGHING; DIABETES MELLITUS; DISEASE TRANSMISSION; DYSPNEA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEVER; FUNGAL COLONIZATION; GAMMA DELTA T LYMPHOCYTE; HEADACHE; HEALTH CARE PERSONNEL; HEART ARRHYTHMIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; HYPERGLYCEMIA; HYPERKALEMIA; HYPOGLYCEMIA; LACTATE DEHYDROGENASE BLOOD LEVEL; LUNG EDEMA; LUNG EMBOLISM; LYMPHADENOPATHY; MULTIPLE MYELOMA; NONHUMAN; PANCREATITIS; PANCYTOPENIA; PLEURA EFFUSION; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTIS PNEUMONIA; PNEUMOCYSTOSIS; POLYMERASE CHAIN REACTION; RASH; REVIEW; SACCHAROMYCES CEREVISIAE; SARCOIDOSIS; SCHIZOSACCHAROMYCES POMBE; SHOCK; SIMIAN IMMUNODEFICIENCY VIRUS; STEVENS JOHNSON SYNDROME; THORAX RADIOGRAPHY; TRYPANOSOMA CRUZI;

CARRIER STATE; HIV INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST; PNEUMOCYSTIS JIROVECII; PNEUMONIA, PNEUMOCYSTIS;

PNEUMOCYSTIS; PNEUMOCYSTIS JIROVECII;

EID: 84859518165     PISSN: 08938512     EISSN: 10986618     Source Type: Journal    
DOI: 10.1128/CMR.00013-12     Document Type: Review

References (328)

1. Abouya YL, et al. 1992. Pneumocystis carinii pneumonia. An uncommon cause of death in African patients with acquired immunodeficiency syndrome. Am. Rev. Respir. Dis. 145:617-620.
2. Afessa B, Green B. 2000. Clinical course, prognostic factors, and outcome prediction for HIV patients in the ICU. The PIP (pulmonarycom-plications, ICU support, and prognostic factors in hospitalized patients with HIV) study. Chest 118:138-145.
3. Agostini C, Zambello R, Trentin L, Semenzato G. 1995. T lymphocytes with gamma/delta T-cell receptors in patients with AIDS and Pneumocystis carinii pneumonia. AIDS 9:203-204.
4. An CL, Gigliotti F, Harmsen AG. 2003. Exposure of immunocompetent adult mice to Pneumocystis carinii f. sp. muris by cohousing: growth of P. carinii f. sp. muris and host immune response. Infect. Immun. 71:page typefirst2065/pagex-/xpage typelast2070/page.
5. Annaloro C, Della Volpe A, Usardi P, Lambertenghi Deliliers G. 2006. Caspofungin treatment of Pneumocystis pneumonia during conditioning for bone marrow transplantation. Eur. J. Clin. Microbiol. Infect. Dis. 25:52-54.
6. Anonymous. 1981. Pneumocystis pneumonia-Los Angeles. MMWR Morb. Mortal. Wkly. Rep. 30:250-252.
7. Anonymous. 2009. HIV/AIDS surveillance report, p. 19. Centers for Disease Control and Prevention, Atlanta, GA.
8. Anonymous. 2008. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents. Centers for Disease Control and Prevention, Atlanta, GA.
9. Atzori C, et al. 1998. Combined use ofblood and oropharyngeal samples for noninvasive diagnosis of Pneumocystis carinii pneumonia using the polymerase chain reaction. Eur. J. Clin. Microbiol. Infect. Dis. 17:241-246.
10. Azoulay E, et al. 2009. Polymerase chain reaction for diagnosing Pneu-mocystis pneumonia in non-HIV immunocompromised patients with pulmonary infiltrates. Chest 135:655-661.
11. Bakeera-Kitaka S, Musoke P, Downing R, Tumwine JK. 2004. Pneu-mocystis carinii in children with severe pneumonia at Mulago Hospital, Uganda. Ann. Trop. Paediatr. 24:227-235.
12. Bartlett MS, et al. 1998. Antibody to Pneumocystis carinii protects rats and mice from developing pneumonia. Clin. Diagn. Lab Immunol. 5:74-77.
13. Beard CB, et al. 2000. Genetic variation in Pneumocystis carinii isolates from different geographic regions: implications for transmission. Emerg. Infect. Dis. 6:265-272.
14. Beard CB, et al. 2005. Genetic differences in Pneumocystis isolates recovered from immunocompetent infants and from adults with AIDS: epidemiological implications. J. Infect. Dis. 192:1815-1818.
15. Beck JM, et al. 2003. T cell costimulatory molecule function determines susceptibility to infection with Pneumocystis carinii in mice. J. Immunol. 171:1969-1977.
16. Beck JM, Harmsen AG. 1998. Lymphocytes in host defense against Pneumocystis carinii. Semin. Respir. Infect. 13:330-338.
17. Beck JM, et al. 1996. Role of CD8+ lymphocytes in host defense against Pneumocystis carinii in mice. J. Lab. Clin. Med. 128:477-487.
18. Beck JM, et al. 1991. Inflammatory responses to Pneumocystis carinii in mice selectively depleted of helper T lymphocytes. Am. J. Respir. Cell Mol. Biol. 5:186-197.
19. Beck JM, Warnock ML, Kaltreider HB, Shellito JE. 1993. Host defenses against Pneumocystis carinii in mice selectively depleted of CD4+ lymphocytes. Chest 103:116S-118S.
20. Benfield T, Atzori C, Miller RF, Helweg-Larsen J. 2008. Second-line salvage treatment of AIDS-associated Pneumocystis jirovecii pneumonia: a case series and systematic review. J. Acquir. Immune Defic. Syndr. 48:63-67.
21. Benfield TL, et al. 1997. The major surface glycoprotein of Pneumocystis carinii induces release and gene expression of interleukin-8 and tumor necrosis factor alpha in monocytes. Infect. Immun. 65:4790-4794.
22. Bishop LR, Kovacs JA. 2003. Quantitation of anti-Pneumocystis jiroveci antibodies in healthy persons and immunocompromised patients. J. Infect. Dis. 187:1844-1848.
23. Board KF, et al. 2003. Experimental Pneumocystis carinii pneumonia in simian immunodeficiency virus-infected rhesus macaques. J. Infect. Dis. 187:576-588.
24. Bozzette SA, et al. 1990. A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. California Collaborative Treatment Group. N. Engl. J. Med. 323:1451-1457.
25. Brown GD, Gordon S. 2005. Immune recognition of fungal beta- glucans. Cell. Microbiol. 7:471-479.
26. Buchacz K, et al. 2010. AIDS-defining opportunistic illnesses in US patients, 1994-2007: a cohort study. AIDS 24:1549-1559.
27. Burke BA, Good RA. 1973. Pneumocystis carinii infection. Medicine 52:23-51.
28. Calderon E, et al. 2004. Pneumocystis jiroveci isolates with dihydro-pteroate synthase mutations in patients with chronic bronchitis. Eur. J. Clin. Microbiol. Infect. Dis. 23:545-549.
29. Calderon EJ. 2010. Pneumocystis infection: seeing beyond the tip of the iceberg. Clin. Infect. Dis. 50:354-356.
30. Calderon EJ, Regordan C, Medrano FJ, Ollero M, Varela JM. 1996. Pneumocystis carinii infection in patients with chronic bronchial disease. Lancet 347:977.
31. Calderon EJ, et al. 2007. Systemic inflammation in patients with chronic obstructive pulmonary disease who are colonized with Pneumocystis jiroveci. Clin. Infect. Dis. 45:e17-e19.
32. Casanova-Cardiel L, Leibowitz MJ. 1997. Presence of Pneumocystis carinii DNA in pond water. J. Eukaryot. Microbiol. 44:28S.
33. Castro M, et al. 1993. Pneumocystis carinii induces the release of arachidonic acid and its metabolites from alveolar macrophages. Am. J. Respir. Cell Mol. Biol. 9:73-81.
34. Chagas C. 1909. Nova tripanosomiaze humana. Estudos sobre a mor-folojia e o ciclo evolutivo do Schistotrypanum cruzi n. g., n. sp., ajente etiologico de nova entidade morbida do homen. Mem. Inst. Oswaldo Cruz 1:159-218.
35. Chave JP, David S, Wauters JP, Van Melle G, Francioli P. 1991. Transmission ofPneumocystis carinii from AIDS patients to other immu-nosuppressed patients: a cluster of Pneumocystis carinii pneumonia in renal transplant recipients. AIDS 5:927-932.
36. Chen W, Gigliotti F, Harmsen AG. 1993. Latency is not an inevitable outcome ofinfectionwith Pneumocystis carinii. Infect. Immun. 61:5406-5409.
37. Cheng BH, et al. 2010. Microarray studies on effects of Pneumocystis carinii infection on global gene expression in alveolar macrophages. BMC Microbiol. 10:103.
38. Cheung YF, Chan CF, Lee CW, Lau YL. 1994. An outbreak of Pneu- mocystis carinii pneumonia in children with malignancy. J. Paediatr. Child Health 30:173-175.
39. Choukri F, et al. 2010. Quantification and spread of Pneumocystis jirove-cii in the surrounding air ofpatients with Pneumocystis pneumonia. Clin. Infect. Dis. 51:259-265.
40. Christensen PJ, et al. 2008. Pneumocystis murina infection and cigarette smoke exposure interact to cause increased organism burden, development of airspace enlargement, and pulmonary inflammation in mice. Infect. Immun. 76:3481-3490.
41. Chung KF, 2001. Cytokines in chronic obstructive pulmonary disease. Eur. Respir. J. Suppl. 34:50s-59s.
42. Conte JE, Jr, et al. 1990. Intravenous or inhaled pentamidine for treating Pneumocystis carinii pneumonia in AIDS. A randomized trial. Ann. Intern. Med. 113:203-209.
43. Conte JE, Jr, Hollander H, Golden JA. 1987. Inhaled or reduced-dose intravenous pentamidine for Pneumocystis carinii pneumonia. A pilot study. Ann. Intern. Med. 107:495-498.
44. Croix DA, et al. 2002. Alterations in T lymphocyte profiles of bronchoal-veolar lavage fluid from SIV- and Pneumocystis carinii-coinfected rhesus macaques. AIDS Res. Hum. Retroviruses 18:391-401.
45. Crothers K, et al. 2005. Severity and outcome of HIV-associated Pneu-mocystis pneumonia containing Pneumocystis jirovecii dihydropteroate synthase gene mutations. AIDS 19:801-805.
46. Crothers K, et al. 2011. Decreased serum antibody responses to recom-binant Pneumocystis antigens in HIV-infected and uninfected current smokers. Clin. Vaccine Immunol. 18:380-386.
47. Crum NF, et al. 2006. Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras. J. Acquir. Immune Defic.Syndr. 41:194-200.
48. Curtis JR, Yarnold PR, Schwartz DN, Weinstein RA, Bennett CL. 2000. Improvements inoutcomes ofacute respiratoryfailureforpatients with human immunodeficiency virus-related Pneumocystis carinii pneumonia. Am. J. Respir. Crit. Care Med. 162:393-398.
49. Cushion MT. 2010. Are members of the fungal genus Pneumocystis (a) commensals; (b) opportunists; (c) pathogens; or (d) all of the above? PLoS Pathog. 6:e1001009.
50. Cushion MT, et al. 2010. Echinocandin treatment of Pneumocystis pneumonia in rodent models depletes cysts leaving trophic burdens that cannot transmit the infection. PLoS One 5:e8524.
51. Daly K, et al. 2009. Geographical variation in serological responses to recombinant Pneumocystis jirovecii major surface glycoprotein antigens. Clin. Microbiol. Infect. 15:937-942.
52. Daly KR, et al. 2002. Serologic responses to epitopes ofthe major surface glycoprotein of Pneumocystis jiroveci differ in human immunodeficiency virus-infected and uninfected persons. J. Infect. Dis. 186:644-651.
53. Daly KR, et al. 2006. Antibody response to Pneumocystis jirovecii major surface glycoprotein. Emerg. Infect. Dis. 12:1231-1237.
54. Daly KR, Koch J, Levin L, Walzer PD. 2004. Enzyme-linked immu-nosorbent assay and serologic responses to Pneumocystis jiroveci. Emerg. Infect. Dis. 10:848-854.
55. Daly KR, Koch JV, Shire NJ, Levin L, Walzer PD. 2006. Human immunodeficiency virus-infected patients with prior Pneumocystis pneumonia exhibit increased serologic reactivity to several major surface glycoprotein clones. Clin. Vaccine Immunol. 13:1071-1078.
56. de Boer MG, et al. 2007. An outbreak of Pneumocystis jiroveci pneumonia with 1 predominant genotype among renal transplant recipients: interhuman transmission or a common environmental source? Clin. Infect. Dis. 44:1143-1149.
57. de Boer MG, de Fijter JW, Kroon FP. 2011. Outbreaks and clustering of Pneumocystis pneumonia in kidney transplant recipients: a systematic review. Med. Mycol. 49:673-680.
58. de Boer MG, et al. 2011. Beta-D-glucan and S-adenosylmethionine serum levels for the diagnosis of Pneumocystis pneumonia in HIV-negative patients: a prospective study. J. Infect. 62:93-100.
59. de la Horra C, et al. 2004. Association between human-Pneumocystis infection and small-cell lung carcinoma. Eur. J. Clin. Invest. 34:229-235.
60. Delanoe P, Delanoe M. 1912. Sur les rapports des kystes de Carini du poumon des rats avec le Trypanosoma lewisi. C. R. Hebd. Seances Acad. Sci. 155:658-659.
61. DeLorenzo LJ, Huang CT, Maguire GP, Stone DJ. 1987. Roentgeno-graphic patterns ofPneumocystis carinii pneumonia in 104 patients with AIDS. Chest 91:323-327.
62. Demanche C, et al. 2001. Phylogeny of Pneumocystis carinii from 18 primate species confirms host specificity and suggests coevolution. J. Clin. Microbiol. 39:2126-2133.
63. Demanche C, et al. 2005. Molecular and serological evidence of Pneumocystis circulation in a social organization of healthy macaques (Macaca fascicularis). Microbiology 151:3117-3125.
64. Desmet S, et al. 2009. Serum (1-3)-beta-D-glucan as a tool for diagnosis ofPneumocystis jirovecii pneumonia in patients with human immunodeficiency virus infection or hematological malignancy. J. Clin. Microbiol. 47:3871-3874.
65. Dickson SJ, et al. 2007. Survival of HIV-infected patients in the intensive care unit in the era of highly active antiretroviral therapy. Thorax 62: 964-968.
66. Ding K, et al. 2005. Impaired recognition by Toll-like receptor 4 is responsible for exacerbated murine Pneumocystis pneumonia. Microbes Infect. 7:195-203.
67. Djawe K, et al. 2010. Seroepidemiological study of Pneumocystis jirovecii infection in healthy infants in Chile using recombinant fragments of the P. jirovecii major surface glycoprotein. Int. J. Infect. Dis. 14:e1060-e1066.
68. Djawe K, et al. 2010. Serum antibody levels to the Pneumocystis jirovecii major surface glycoprotein in the diagnosis of P. jirovecii pneumonia in HIV+ patients. PLoS One 5:e14259.
69. Dohn MN, et al. 2000. Geographic clustering of Pneumocystis carinii pneumoniain patients with HIV infection. Am. J. Respir. Crit. Care Med. 162:1617-1621.
70. Downing JF, Kachel DL, Pasula R, Martin WJ II. 1999. Gamma interferon stimulates rat alveolar macrophages to kill Pneumocystis carinii by L-arginine- and tumor necrosis factor-dependent mechanisms. Infect. Immun. 67:1347-1352.
71. Dubin PJ, Kolls JK. 2008. Th17 cytokines and mucosal immunity. Immunol. Rev. 226:160-171.
72. Dummer JS, et al. 1986. Infections in heart-lung transplant recipients. Transplantation 41:725-729.
73. Edman JC, et al. 1996. A single expression site with a conserved leader sequence regulates variation of expression of the Pneumocystis carinii family ofmajor surface glycoprotein genes. DNA Cell Biol. 15:989-999.
74. Edman JC, et al. 1988. Ribosomal RNA sequence shows Pneumocystis carinii to be a member ofthe fungi. Nature 334:519-522.
75. Eitner F, et al. 2011. Risk factors for Pneumocystis jiroveci pneumonia (PcP) in renal transplant recipients. Nephrol. Dial Transplant. 26:2013-2017.
76. Empey KM, Hollifield M, Garvy BA. 2007. Exogenous heat-killed Esch-erichia coli improves alveolar macrophage activity and reduces Pneumo-cystis carinii lung burden in infant mice. Infect. Immun. 75:3382-3393.
77. Enomoto T, et al. 2010. Differences in the clinical characteristics of Pneumocystis jirovecii pneumonia in immunocompromised patients with and without HIV infection. Respirology 15:126-131.
78. Ezekowitz RA, et al. 1991. Uptake of Pneumocystis carinii mediated by the macrophage mannose receptor. Nature 351:155-158.
79. Fei MW, et al. 2009. Predicting mortality from HIV-associated Pneu-mocystis pneumonia at illness presentation: an observational cohort study. Thorax 64:1070-1076.
80. Festic E, Gajic O, Limper AH, Aksamit TR. 2005. Acute respiratory failure due to Pneumocystis pneumonia in patients without human immunodeficiency virus infection: outcome and associated features. Chest 128:573-579.
81. Finkelman MA. 2010. Pneumocystis jirovecii infection: cell wall (1→3)-β-D-glucan biology and diagnostic utility. Crit. Rev. Microbiol. 36:271-281.
82. Finlay GA, et al. 1997. Matrix metalloproteinase expression and production by alveolar macrophages in emphysema. Am. J. Respir. Crit. CareMed. 156:240-247.
83. Fischer S, et al. 2001. The use of oral washes to diagnose Pneumocystis carinii pneumonia: a blinded prospective study using a polymerase chain reaction-based detection system. J. Infect. Dis. 184:1485-1488.
84. Fisk DT, Meshnick S, Kazanjian PH. 2003. Pneumocystis carinii pneumonia in patients in the developing world who have acquired immunodeficiency syndrome. Clin. Infect. Dis. 36:70-78.
85. Forrest DM, et al. 1998. Validation of the modified multisystem organ failure score as a predictor of mortality in patients with AIDS-related Pneumocystis carinii pneumonia and respiratory failure. Chest 114:199-206.
86. Forthal DN, et al. 2007. FcgammaRIIa genotype predicts progression of HIV infection. J. Immunol. 179:7916-7923.
87. Fraser IP, et al. 2000. Pneumocystis carinii enhances soluble mannose receptor production by macrophages. Microbes Infect. 2:1305-1310.
88. Fujisawa T, et al. 2009. Real-time PCR is more specific than conventional PCR for induced sputum diagnosis of Pneumocystis pneumonia in immunocompromised patients without HIV infection. Respirology 14: 203-209.
89. Furuta T, Fujiwara K, Yamanouchi K, Ueda K. 1985. Detection of antibodies to Pneumocystis carinii by enzyme-linked immunosorbent assay in experimentally infected mice. J. Parasitol. 71:522-523.
90. Gal SL, et al. 2010. Pneumocystis jirovecii and cystic fibrosis in France. Scand. J. Infect. Dis. 42:225-227.
91. Garvy BA, Wiley JA, Gigliotti F, Harmsen AG. 1997. Protection against Pneumocystis carinii pneumonia by antibodies generated from either T helper 1 or T helper 2 responses. Infect. Immun. 65:5052-5056.
92. Gautam H, et al. 2009. Epidemiology ofopportunistic infections and its correlation with CD4 T-lymphocyte counts and plasma viral load among HIV-positive patients at a tertiary care hospital in India. J. Int. Assoc. Physicians AIDS Care 8:333-337.
93. Gerrard MP, Eden OB, Jameson B, Craft AW. 1987. Serological study of Pneumocystis carinii infection in the absence of immunosuppression. Arch. Dis. Child. 62:177-179.
94. Gianella S, et al. 2010. Molecular evidence of interhuman transmission in an outbreak of Pneumocystis jirovecii pneumonia among renal transplant recipients. Transpl. Infect. Dis. 12:1-10.
95. Gigliotti F. 1992. Host species-specific antigenic variation of a mannosylated surface glycoprotein of Pneumocystis carinii. J. Infect. Dis. 165: 329-336.
96. Gigliotti F, Garvy BA, Haidaris CG, Harmsen AG. 1998. Recognition of Pneumocystis carinii antigens by local antibody-secreting cells following resolution of P. carinii pneumonia in mice. J. Infect. Dis. 178:235-242.
97. Gigliotti F, Haidaris CG, Wright TW, Harmsen AG. 2002. Passive intranasal monoclonal antibody prophylaxis against murine Pneumocystis carinii pneumonia. Infect. Immun. 70:1069-1074.
98. Gigliotti F, Harmsen AG, Haidaris CG, Haidaris PJ. 1993. Pneumocystis carinii is not universally transmissible between mammalian species. Infect. Immun. 61:2886-2890.
99. Gigliotti F, Harmsen AG, Wright TW. 2003. Characterization of transmission of Pneumocystis carinii f. sp. muris through immunocompetent BALB/c mice. Infect. Immun. 71:3852-3856.
100. Gigliotti F, Hughes WT. 1988. Passive immunoprophylaxis with specific monoclonal antibody confers partial protection against Pneumocystis carinii pneumonitis in animal models. J. Clin. Invest. 81:1666-1668.
101. Gill VJ, et al. 1987. Detection of Pneumocystis carinii by fluorescent-antibody stain using a combination of three monoclonal antibodies. J. Clin. Microbiol. 25:1837-1840.
102. Gingo MR, et al. 2011. Serologic responses to Pneumocystis proteins in human immunodeficiency virus patients with and without Pneumocystis jirovecii pneumonia. J. Acquir. Immune Defic. Syndr. 57:190-196.
103. Godeau B, et al. 1994. Pneumocystis carinii pneumonia in the course of connective tissue disease: report of 34 cases. J. Rheumatol. 21:246-251.
104. Goodridge HS, Wolf AJ, Underhill DM. 2009. Beta-glucan recognition by the innate immune system. Immunol. Rev. 230:38-50.
105. Green H, Paul M, Vidal L, Leibovici L. 2007. Prophylaxis for Pneumo-cystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst. Rev. 18:CD005590.
106. Gryzan S, et al. 1988. Unexpectedly high incidence of Pneumocystis carinii infection after lung-heart transplantation. Implications for lung defense and allograft survival. Am. Rev. Respir. Dis. 137:1268-1274.
107. Gutierrez S, et al. 2011. High prevalence of Pneumocystis jiroveci colonization among young HIV-infected patients. J. Adolesc. Health 48:103-105.
108. Hanano R, Reifenberg K, Kaufmann SH. 1996. Naturally acquired Pneumocystis carinii pneumonia in gene disruption mutant mice: roles of distinct T-cell populations in infection. Infect. Immun. 64:3201-3209.
109. Harigai M, Koike R, Miyasaka N. 2007. Pneumocystis pneumonia associated with infliximab in Japan. N. Engl. J. Med. 357:1874-1876.
110. Harmsen AG, Chen W, Gigliotti F. 1995. Active immunity to Pneumo-cystis carinii reinfection in T-cell-depleted mice. Infect. Immun. 63: 2391-2395.
111. Hauser P, et al. 2011. Multicenter, prospective clinical evaluation of respiratory samples from subjects at risk for Pneumocystis jirovecii using a commercial real-time PCR assay. J. Clin. Microbiol. 49:1872-1878.
112. Hauser PM, et al. 2010. Interhuman transmission as a potential key parameter for geographical variation in the prevalence of Pneumocystis jirovecii dihydropteroate synthase mutations. Clin. Infect. Dis. 51: e28-33.
113. Held J, Koch M, Reischl U, Danner T, Serr A. 2011. Serum (1→3)-beta-D-glucan measurement as early indicator for Pneumocystis jirovecii pneumonia and evaluation of its prognostic value. Clin. Microbiol. Infect. 17:595-602.
114. Helweg-Larsen J, Benfield T, Atzori C, Miller RF. 2009. Clinical efficacy of first- and second-line treatments for HIV-associated Pneumocystis jirovecii pneumonia: a tri-centre cohort study. J. Antimicrob. Chemother. 64:1282-1290.
115. Helweg-Larsen J, Benfield TL, Eugen-Olsen J, Lundgren JD, Lundgren B. 1999. Effects of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of AIDS-associated P. carinii pneumonia. Lancet 354:1347-1351.
116. Helweg-Larsen J, Jensen JS, Dohn B, Benfield TL, Lundgren B. 2002. Detection of Pneumocystis DNA in samples from patients suspected of bacterial pneumonia-a case-control study. BMC Infect. Dis. 2:28.
117. Hoffman OA, Standing JE, Limper AH. 1993. Pneumocystis carinii stimulates tumor necrosis factor-alpha release from alveolar macro-phages through a beta-glucan-mediated mechanism. J. Immunol. 150: 3932-3940.
118. Hollifield M, Bou Ghanem E, de Villiers WJ, Garvy BA. 2007. Scavenger receptor A dampens induction of inflammation in response to the fungal pathogen Pneumocystis carinii. Infect. Immun. 75:3999-4005.
119. Hoyte JS, Standing JE, Limper AH. 1997. Steady-state effects of vitronectin and fibronectin on the binding, uptake, and degradation of Pneumocystis carinii in rat alveolar macrophages. Inflammation 21:335-345.
120. Huang L, et al. 2000. Sulfa or sulfone prophylaxis and geographic region predict mutations in the Pneumocystis carinii dihydropteroate synthase gene. J. Infect. Dis. 182:1192-1198.
121. Huang L, et al. 2003. Pneumocystis colonization in HIV-infected patients. J. Eukaryot. Microbiol. 50(Suppl):616-617.
122. Huang L, Morris AM, Beard CB. 2001. Pneumocystis carinii dihydrop-teroate synthase mutations and treatment with sulfa or sulfone regimens: a proposal for standardized definitions for clinical evaluation. J. Eukaryot. Microbiol. Suppl:180S-181S.
123. Huang L, Murray JF. 2005. A rose is a rose: but what about Pneumocystis pneumonia? Int. J. Tuberc. Lung Dis. 9:1297-1298.
124. Huggett JF, et al. 2008. Development and evaluation of a real-time PCR assay for detection of Pneumocystis jirovecii DNA in bronchoalveolar lavage fluid of HIV-infected patients. Thorax 63:154-159.
125. Hughes WT, et al. 1975. Intensity of immunosuppressive therapy and the incidence of Pneumocystis carinii pneumonitis. Cancer 36:2004-2009.
126. Hugle B, et al. 2010. Pneumocystis jiroveci pneumonia following ritux-imab treatment in Wegener's granulomatosis. Arthritis Care Res. 62: 1661-1664.
127. Icenhour CR, Rebholz SL, Collins MS, Cushion MT. 2001. Widespread occurrence of Pneumocystis carinii in commercial rat colonies detected using targeted PCR and oral swabs. J. Clin. Microbiol. 39:3437-3441.
128. Iikuni N, et al. 2006. Evaluation of Pneumocystis pneumonia infection risk factors in patients with connective tissue disease. Mod. Rheumatol. 16:282-288.
129. Inoue M, et al. 2011. Critical role of intracellular osteopontin in anti-fungal innate immune responses. J. Immunol. 186:19-23.
130. Ishimine T, Kawakami K, Nakamoto A, Saito A. 1995. Analysis of cellular response and gamma interferon synthesis in bronchoalveolar lavage fluid and lung homogenate of mice infected with Pneumocystis carinii. Microbiol. Immunol. 39:49-58.
131. Ito M, et al. 2000. Prophylactic effect of FK463, a novel antifungal lipopeptide, against Pneumocystis carinii infection in mice. Antimicrob. Agents Chemother. 44:2259-2262.
132. Jarboui MA, et al. 2010. Molecular diagnosis of Pneumocystis jiroveci pneumonia in immunocompromised patients. Mycoses 53:329-333.
133. Jensen L, et al. 2010. Infrequent detection of Pneumocystis jirovecii by PCR in oral wash specimens from TB patients with or without HIV and healthy contacts in Tanzania. BMC Infect. Dis. 10:140.
134. Jirovec O. 1954. Pneumocystis carinii pneumonia in children. Pediatr. Listy. 9:199-202.
135. Jones TC. 1996. The effect of granulocyte-macrophage colony stimulating factor (rGM-CSF) on macrophage function in microbial disease. Med. Oncol. 13:141-147.
136. Kagi MK, Fierz W, Grob PJ, Russi EW. 1993. High proportion of gamma-delta T cell receptor positive T cells in bronchoalveolar lavage and peripheral blood of HIV-infected patients with Pneumocystis carinii pneumonias. Respiration 60:170-177.
137. Kales CP, Murren JR, Torres RA, Crocco JA. 1987. Early predictors of in-hospital mortality for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Arch. Intern. Med. 147:1413-1417.
138. Kamboj M, Weinstock D, Sepkowitz KA. 2006. Progression of Pneu-mocystis jiroveci pneumonia in patients receiving echinocandin therapy. Clin. Infect. Dis. 43:e92-e94.
139. Kaneshiro ES, Maiorano JN. 1996. Survival and infectivity of Pneumo-cystis carinii outside the mammalian host. J. Eukaryot Microbiol. 43:35S.
140. Kaplan JE, et al. 2009. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm. Rep. 58:1-207.
141. Kaplan JE, et al. 2000. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin. Infect. Dis. 30(Suppl 1):S5-S14.
142. Kasolo F, et al. 2002. Identification of Pneumocystis carinii DNA by polymerase chain reaction in necropsy lung samples from children dying ofrespiratory tract illnesses. J. Pediatr. 140:367-369.
143. Kaur N, Mahl TC. 2007. Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases. Dig. Dis. Sci. 52:1481-1484.
144. Kazanjian P, et al. 2000. Pneumocystis carinii mutations are associated with duration of sulfa or sulfone prophylaxis exposure in AIDS patients. J. Infect. Dis. 182:551-557.
145. Kazanjian P, et al. 1998. Pneumocystis carinii mutations associated with sulfa and sulfone prophylaxis failures in AIDS patients. AIDS 12:873-878.
146. Keely SP, Baughman RP, Smulian AG, Dohn MN, Stringer JR. 1996. Source of Pneumocystis carinii in recurrent episodes of pneumonia in AIDS patients. AIDS 10:881-888.
147. Keely SP, Stringer JR. 1997. Sequences of Pneumocystis carinii f. sp. hominis strains associated with recurrent pneumonia vary at multiple loci. J. Clin. Microbiol. 35:2745-2747.
148. Keely SP, Stringer JR. 2009. Complexity of the MSG gene family of Pneumocystis carinii. BMC Genomics 10:367.
149. Keely SP, et al. 1995. Genetic variation among Pneumocystis carinii hominis isolates in recurrent pneumocystosis. J. Infect. Dis. 172:595-598.
150. Kelley CF, et al. 2009. Trends in hospitalizations for AIDS-associated Pneumocystis jirovecii pneumonia in the United States (1986 to 2005). Chest 136:190-197.
151. Kennedy CA, Goetz MB. 1992. Atypical roentgenographic manifestations of Pneumocystis carinii pneumonia. Arch. Intern. Med. 152:1390-1398.
152. Khouli H, et al. 2005. Outcome of critically ill human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy. J. Intensive Care Med. 20:327-333.
153. Kling HM, Shipley TW, Patil S, Morris A, Norris KA. 2009. Pneumocystis colonization in immunocompetent and simian immunodeficiency virus-infected cynomolgus macaques. J. Infect. Dis. 199:89-96.
154. Kling HM, et al. 2010. Relationship of Pneumocystis jiroveci humoral immunity to prevention of colonization and chronic obstructive pulmonary disease in a primate model of HIV infection. Infect. Immun. 78: 4320-4330.
155. Kolls JK, Beck JM, Nelson S, Summer WR, Shellito J. 1993. Alveolar macrophage release of tumor necrosis factor during murine Pneumocystis carinii pneumonia. Am. J. Respir. Cell Mol. Biol. 8:370-376.
156. Kolls JK, et al. 1999. IFN-gammaand CD8+ T cells restore host defenses against Pneumocystis carinii in mice depleted of CD4+ T cells. J. Immunol. 162:2890-2894.
157. Komano Y, et al. 2009. Pneumocystis jiroveci pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case-control study of 21 patients. Arthritis Rheum. 61:305-312.
158. Kovacs JA, et al. 1988. Identification of antigens and antibodies specific for Pneumocystis carinii. J. Immunol. 140:2023-2031.
159. Kovacs JA, et al. 1984. Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann. Intern. Med. 100:663-671.
160. Kovacs JA, Masur H. 2009. Evolving health effects of Pneumocystis: one hundred years ofprogress in diagnosis and treatment. JAMA 301:2578-2585.
161. Kovacs JA, et al. 1993. Multiple genes encode the major surface glyco-protein ofPneumocystis carinii. J. Biol. Chem. 268:6034-6040.
162. Koziel H, et al. 1998. Reduced binding and phagocytosis ofPneumocystis carinii by alveolar macrophages from persons infected with HIV-1 correlates with mannose receptor downregulation. J. Clin. Invest. 102:1332-1344.
163. Koziel H, Li X, Armstrong MY, Richards FF, Rose RM. 2000. Alveolar macrophages from human immunodeficiency virus-infected persons demonstrate impaired oxidative burst response to Pneumocystis carinii in vitro. Am. J. Respir. Cell Mol. Biol. 23:452-459.
164. Kurokawa T, Kaya H, Yoshida T. 2010. Two cases of Pneumocystis jiroveci pneumonia with non-Hodgkin's lymphoma after CHOP-based chemotherapy containing rituximab. J. Clin. Exp. Hematop. 50:159-162.
165. Kutty G, Kovacs JA. 2003. A single-copy gene encodes Kex1, a serine endoprotease of Pneumocystis jiroveci. Infect. Immun. 71:571-574.
166. Kyeyune R, et al. 2010. Causes of early mortality in HIV-infected TB suspects in an East African referral hospital. J. Acquir. Immune Defic. Syndr. 55:446-450.
167. Laakkonen J, Fisher RN, Case TJ. 2001. Pneumocystosis in wild small mammals from California. J. Wildl. Dis. 37:408-412.
168. Laakkonen J, Fisher RN, Case TJ. 2001. Spatial analysis on the occurrence of Pneumocystis carinii in the shrew Notiosorex crawfordi in fragmented landscape in southern California. J. Eukaryot. Microbiol. Suppl: 111S-112S.
169. Larsen HH, et al. 2004. A prospective, blinded study of quantitative touch-down polymerase chain reaction using oral-wash samples for diagnosis of Pneumocystis pneumonia in HIV-infected patients. J. Infect. Dis. 189:1679-1683.
170. Larsen HH, et al. 2007. Primary Pneumocystis infection in infants hospitalized with acute respiratory tract infection. Emerg. Infect. Dis. 13:66-72.
171. Lasbury ME, Durant PJ, Bartlett MS, Smith JW, Lee CH. 2003. Correlation of organism burden and alveolar macrophage counts during infection with Pneumocystis carinii and recovery. Clin. Diagn. Lab Immunol. 10:293-302.
172. Lee CH, et al. 1996. Prevalence of various Pneumocystis carinii sp. f. hominis types in different geographical locations. J. Eukaryot. Microbiol. 43:37S.
173. Lee LH, et al. 2000. Molecular characterization of KEX1, a kexin-like protease in mouse Pneumocystis carinii. Gene 242:141-150.
174. Leibovitz E, et al. 1995. Comparison of PCR and standard cytological staining for detection ofPneumocystis carinii from respiratoryspecimens from patients with or at high risk for infection by human immunodeficiency virus. J. Clin. Microbiol. 33:3004-3007.
175. Leigh TR, Kangro HO, Gazzard BG, Jeffries DJ, Collins JV. 1993. DNA amplification by the polymerase chain reaction to detect sub-clinical Pneumocystis carinii colonization in HIV-positive and HIV-negative male homosexuals with and without respiratory symptoms. Respir. Med. 87:525-529.
176. Leigh TR, Millett MJ, Jameson B, Collins JV. 1993. Serum titres of Pneumocystis carinii antibody in health care workers caring for patients with AIDS. Thorax 48:619-621.
177. Limper AH. 1995. Adhesive glycoproteins in the pathogenesis of Pneu-mocystis carinii pneumonia: host defense or microbial offense? J. Lab. Clin. Med. 125:12-13.
178. Limper AH, et al. 2011. An official American Thoracic Society statement: treatment offungalinfections inadultpulmonaryandcriticalcare patients. Am. J. Respir. Crit. Care Med. 183:96-128.
179. Limper AH, Offord KP, Smith TF, Martin WJ II. 1989. Pneumocystis carinii pneumonia. Differences in lung parasite number and inflammation in patients with and without AIDS. Am. Rev. Respir. Dis. 140:1204-1209.
180. Limper AH, Standing JE, Hoffman OA, Castro M, Neese LW. 1993. Vitronectin binds to Pneumocystis carinii and mediates organism attachment to cultured lung epithelial cells. Infect. Immun. 61:4302-4309.
181. Lugli EB, Allen AG, Wakefield AE. 1997. A Pneumocystis carinii multi-gene family with homology to subtilisin-like serine proteases. Microbiology 143:2223-2236.
182. Lugli EB, Bampton ET, Ferguson DJ, Wakefield AE. 1999. Cell surface protease PRT1 identified in the fungal pathogen Pneumocystis carinii. Mol. Microbiol. 31:1723-1733.
183. Lund FE, et al. 2006. B cells are required for generation of protective effector and memory CD4 cells in response to Pneumocystis lung infection. J. Immunol. 176:6147-6154.
184. Lund FE, Schuer K, Hollifield M, Randall TD, Garvy BA. 2003. Clearance of Pneumocystis carinii in mice is dependent on B cells but not on P. carinii-specific antibody. J. Immunol. 171:1423-1430.
185. Lundberg BE, Davidson AJ, Burman WJ. 2000. Epidemiology of Pneumocystis carinii pneumonia in an era ofeffective prophylaxis: the relative contribution of non-adherence and drug failure. AIDS 14:2559-2566.
186. Lundgren B, et al. 1997. Transmission of Pneumocystis carinii from patients to hospital staff. Thorax 52:422-424.
187. Lundgren B, Jungstrbm I, Rothman LP, Elvin K, Lundgren JD. 1996. Antibody responses to Pneumocystis carinii in hospital personal with and without exposure to patients with P. carinii pneumonia. J. Eukaryot. Microbiol. 43:10S.
188. Lundgren B, Lipschik GY, Kovacs JA. 1991. Purification and characterization of a major human Pneumocystis carinii surface antigen. J. Clin. Invest. 87:163-170.
189. Lundgren JD, et al. 1997. Regional differences in use of antiretroviral agentsandprimaryprophylaxisin3122EuropeanHIV-infectedpatients. EuroSIDA Study Group. J. Acquir. Immune Defic. Syndr Hum. Retroviral. 16:153-160.
190. Ma L, Borio L, Masur H, Kovacs JA. 1999. Pneumocystis carinii dihy-dropteroate synthase but not dihydrofolate reductase gene mutations correlate with prior trimethoprim-sulfamethoxazole or dapsone use. J. Infect. Dis. 180:1969-1978.
191. Macy JD, Jr, Weir EC, Compton SR, Shlomchik MJ, Brownstein DG. 2000. Dual infection with Pneumocystis carinii and Pasteurella pneumotropica in B cell-deficient mice: diagnosis and therapy. Comp. Med. 50: 49-55.
192. Mahdavi S, Malyuta R, Semenenko I, Pilipenko T, Thorne C. 2010. Treatment and disease progression in a birth cohort of vertically HIV-1 infected children in Ukraine. BMC Pediatr. 10:85.
193. Mansharamani NG, Balachandran D, Vernovsky I, Garland R, Koziel H. 2000. Peripheralblood CD4 + T-lymphocyte counts duringPneumo-cystis carinii pneumonia in immunocompromised patients without HIV infection. Chest 118:712-720.
194. Marcotte H, et al. 1996. Pneumocystis carinii infection in transgenic B cell-deficient mice. J. Infect. Dis. 173:1034-1037.
195. Maskell NA, et al. 2003. Asymptomatic carriage of Pneumocystis jiroveci in subjects undergoing bronchoscopy: a prospective study. Thorax 58: 594-597.
196. Masur H, Jones TC. 1978. The interaction in vitro of Pneumocystis carinii with macrophages and L-cells. J. Exp. Med. 147:157-170.
197. Masur H, et al. 1981. An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction. N. Engl. J. Med. 305:1431-1438.
198. Matos O, et al. 2001. Effect of oral washes on the diagnosis of Pneumo-cystis carinii pneumonia with a low parasite burden and on detection of organisms in subclinical infections. Eur. J. Clin. Microbiol. Infect. Dis. 20:573-575.
199. Matsumoto Y, Matsuda S, Tegoshi T. 1989. Yeast glucan in the cyst wall of Pneumocystis carinii. J. Protozool. 36:21S-22S.
200. McAllister F, et al. 2004. T cytotoxic-1 CD8+ T cells are effector cells against Pneumocystis in mice. J. Immunol. 172:1132-1138.
201. McCormack FX, Festa AL, Andrews RP, Linke M, Walzer PD. 1997. The carbohydrate recognition domain of surfactant protein A mediates binding to the major surface glycoprotein of Pneumocystis carinii. Bio-chemistry 36:8092-8099.
202. Medrano FJ, et al. 2005. Pneumocystis jirovecii in general population. Emerg. Infect. Dis. 11:245-250.
203. Mei Q, et al. 1998. Characterization of major surface glycoprotein genes of human Pneumocystis carinii and high-level expression of a conserved region. Infect. Immun. 66:4268-4273.
204. Mekinian A, et al. 2011. Pneumocystis jirovecii colonization in patients with systemic autoimmune diseases: prevalence, risk factors of colonization and outcome. Rheumatology 50:569-577.
205. Merali S, Vargas D, Franklin M, Clarkson AB, Jr. 2000. S-adeno-sylmethionine and Pneumocystis carinii. J. Biol. Chem. 275:14958-14963.
206. Meuwissen JH, Tauber I, Leeuwenberg AD, Beckers PJ, Sieben M. 1977. Parasitologic and serologic observations ofinfection with Pneumocystis in humans. J. Infect. Dis. 136:43-49.
207. Milledge J, Kakakios A, Gillis J, Fitzgerald DA. 2003. Pneumocystis carinii pneumonia as a presenting feature of X-linked hyper-IgM syndrome. J. Paediatr. Child Health 39:704-706.
208. Miller RF, Allen E, Copas A, Singer M, Edwards SG. 2006. Improved survival for HIV infected patients with severe Pneumocystis jirovecii pneumonia is independent of highly active antiretroviral therapy. Thorax 61:716-721.
209. Miller RF, Ambrose HE, Wakefield AE. 2001. Pneumocystis carinii f. sp. hominis DNA in immunocompetent health care workers in contact with patients with P. carinii pneumonia. J. Clin. Microbiol. 39:3877-3882.
210. Miller RF, Evans HE, Copas AJ, Cassell JA. 2007. Climate and genotypes of Pneumocystis jirovecii. Clin. Microbiol. Infect. 13:445-448.
211. Moir S, Fauci AS. 2009. B cells in HIV infection and disease. Nat. Rev. Immunol. 9:235-245.
212. Molet S, et al. 2005. Increase in macrophage elastase (MMP-12) in lungs from patients with chronic obstructive pulmonary disease. Inflamm. Res. 54:31-36.
213. Monnet X, et al. 2008. Critical care management and outcome of severe Pneumocystis pneumonia in patients with and without HIV infection. Crit. Care 12:R28.
214. Mori H, et al. 2010. Polymerase chain reaction positivity of Pneumocystis jirovecii during primary lung cancer treatment. Jpn. J. Clin. Oncol. 40: 658-662.
215. Mori S, Cho I, Sugimoto M. 2010. A cluster of Pneumocystis jirovecii infection among outpatients with rheumatoid arthritis. J. Rheumatol. 37:1547-1548.
216. Morris A, et al. 2009. Airway obstruction is increased in Pneumocystis-colonized human immunodeficiency virus-infected outpatients. J. Clin. Microbiol. 47:3773-3776.
217. Morris A, et al. 2004. Prevalence and clinical predictors of Pneumocystis colonization among HIV-infected men. AIDS 18:793-798.
218. Morris A, et al. 2004. Current epidemiology of Pneumocystis pneumonia. Emerg. Infect. Dis. 10:1713-1720.
219. Morris A, et al. 2008. Relationship of Pneumocystis antibody response to severity of chronic obstructive pulmonary disease. Clin. Infect. Dis. 47: e64-e68.
220. Morris A, et al. 2004. Association of chronic obstructive pulmonary disease severity and Pneumocystis colonization. Am. J. Respir. Crit. Care Med. 170:408-413.
221. Morris A, Wachter RM, Luce J, Turner J, Huang L. 2003. Improved survival with highly active antiretroviral therapy in HIV-infected patients with severe Pneumocystis carinii pneumonia. AIDS 17:73-80.
222. Morris A, Wei K, Afshar K, Huang L. 2008. Epidemiology and clinical significance of Pneumocystis colonization. J. Infect. Dis. 197:10-17.
223. Morris AM, Swanson M, Ha H, Huang L. 2000. Geographic distribution of human immunodeficiency virus-associated Pneumocystis carinii pneumonia in San Francisco. Am. J. Respir. Crit. Care Med. 162:1622-1626.
224. Morris DG, et al. 2003. Loss of integrin alpha(v)beta6-mediated TGF-beta activation causes Mmp12-dependent emphysema. Nature 422:169-173.
225. Navin TR, et al. 2001. Effect of mutations in Pneumocystis carinii dihy-dropteroate synthase gene on outcome of P. carinii pneumonia in patients with HIV-1: a prospective study. Lancet 358:545-549.
226. Navin TR, et al. 2000. Risk factors for community-acquired pneumonia among persons infected with human immunodeficiency virus. J. Infect. Dis. 181:158-164.
227. Nelson MP, et al. 2011. IL-33 and M2 a alveolar macrophages promote lung defense against the atypical fungal pathogen Pneumocystis murina. J. Immunol. 186:2372-2381.
228. Nevez G, et al. 1997. High frequency of Pneumocystis carinii sp. f. homi-nis colonization in HIV-negative patients. J. Eukaryot. Microbiol. 44: 36S.
229. Nevez G, et al. 2006. Apparent absence of Pneumocystis jirovecii in healthy subjects. Clin. Infect. Dis. 42:e99-e101.
230. Nevez G, Raccurt C, Jounieaux V, Dei-Cas E, Mazars E. 1999. Pneumocystosis versus pulmonary Pneumocystis carinii colonization in HIV-negative and HIV-positive patients. AIDS 13:535-536.
231. Nevez G, Totet A, Pautard JC, Raccurt C. 2001. Pneumocystis carinii detection using nested-PCR in nasopharyngeal aspirates of immuno-competent infants with bronchiolitis. J. Eukaryot. Microbiol. Suppl.: 122S-123S.
232. Ng VL, et al. 1990. Rapid detection of Pneumocystis carinii using a direct fluorescent monoclonal antibody stain. J. Clin. Microbiol. 28:2228-2233.
233. Nkinin SW, et al. 2009. Evidence for high prevalence of Pneumocystis jirovecii exposure among Cameroonians. Acta Trop. 112:219-224.
234. O'Donnell WJ, Pieciak W, Chertow GM, Sanabria J, Lahive KC. 1998. Clearance of Pneumocystis carinii cysts in acute P. carinii pneumonia: assessment by serial sputum induction. Chest 114:1264-1268.
235. Ognibene FP, et al. 1995. Pneumocystis carinii pneumonia: a major complication of immunosuppressive therapy in patients with Wegener's granulomatosis. Am. J. Respir. Crit. Care Med. 151:795-799.
236. Olsson M, et al. 1998. Identification of Pneumocystis carinii f. sp. hominis gene sequences in filtered air in hospital environments. J. Clin. Microbiol. 36:1737-1740.
237. Opravil M, et al. 1994. Shortcomings of chest radiography in detecting Pneumocystis carinii pneumonia. J. Acquir. Immune Defic. Syndr. 7:39-45.
238. Palella FJ, Jr, et al. 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N. Engl. J. Med. 338:853-860.
239. Pascale JM, et al. 1999. Intranasal immunization confers protection against murine Pneumocystis carinii lung infection. Infect. Immun. 67: 805-809.
240. Peglow SL, et al. 1990. Serologic responses to Pneumocystis carinii antigens in health and disease. J. Infect. Dis. 161:296-306.
241. Peters SE, Wakefield AE, Sinclair K, Millard PR, Hopkin JM. 1992. A search for Pneumocystis carinii in post-mortem lungs by DNA amplification. J. Pathol. 166:195-198.
242. Phair J, et al. 1990. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. Multicenter AIDS Cohort Study Group. N. Engl. J. Med. 322:161-165.
243. Pifer LL, Hughes WT, Stagno S, Woods D. 1978. Pneumocystis carinii infection: evidence for high prevalence in normal and immunosup-pressed children. Pediatrics 61:35-41.
244. Ponce CA, Gallo M, Bustamante R, Vargas SL. 2010. Pneumocystis colonization is highly prevalent in the autopsied lungs of the general population. Clin. Infect. Dis. 50:347-353.
245. Powles MA, et al. 1998. Efficacy of MK-991 (L-743,872), a semisynthetic pneumocandin, in murine models of Pneumocystis carinii. Antimicrob. Agents Chemother. 42:1985-1989.
246. Powles MA, McFadden DC, Pittarelli LA, Schmatz DM. 1992. Mouse model for Pneumocystis carinii pneumonia that uses natural transmission to initiate infection. Infect. Immun. 60:1397-1400.
247. Pulvirenti J, Herrera P, Venkataraman P, Ahmed N. 2003. Pneumo-cystis carinii pneumonia in HIV-infected patients in the HAART era. AIDS Patient Care STDS 17:261-265.
248. Qin S, et al. 2010. Simian immunodeficiency virus infection alters chemokine networks in lung tissues of cynomolgus macaques: association with Pneumocystis carinii infection. Am. J. Pathol. 177:1274-1285.
249. Rabodonirina M, et al. 1997. Rapid detection of Pneumocystis carinii in bronchoalveolar lavage specimens from human immunodeficiency virus-infected patients: use of a simple DNA extraction procedure and nested PCR. J. Clin. Microbiol. 35:2748-2751.
250. Radhi S, Alexander T, Ukwu M, Saleh S, Morris A. 2008. Outcome of HIV-associated Pneumocystis pneumonia in hospitalized patients from 2000 through 2003. BMC Infect. Dis. 8:118.
251. Rapaka RR, et al. 2010. Conserved natural IgM antibodies mediate innate and adaptive immunity against the opportunistic fungus Pneumo-cystis murina. J. Exp. Med. 207:2907-2919.
252. Respaldiza N, et al. 2004. High seroprevalence of Pneumocystis infection in Spanish children. Clin. Microbiol. Infect. 10:1029-1031.
253. Respaldiza N, et al. 2005. Prevalence of colonisation and genotypic characterisation of Pneumocystis jirovecii among cystic fibrosis patients in Spain. Clin. Microbiol. Infect. 11:1012-1015.
254. Rodriguez M, Fishman JA. 2004. Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients. Clin. Microbiol. Rev. 17:770-782.
255. Rose CM, Kimzey SL, Green JM. 2006. The host response of CD28-deficient mice to Pneumocystis infection. Microb. Pathog. 40:23-28.
256. Ross GD, Cain JA, Myones BL, Newman SL, Lachmann PJ. 1987. Specificity of membrane complement receptor type three (CR3) forbeta-glucans. Complement 4:61-74.
257. Roths JB, Sidman CL. 1992. Both immunity and hyperresponsiveness to Pneumocystis carinii result from transfer ofCD4+ but not CD8+ T cells into severe combined immunodeficiency mice. J. Clin. Invest. 90:673-678.
258. Roths JB, Sidman CL. 1993. Single and combined humoral and cell-mediated immunotherapy of Pneumocystis carinii pneumonia in immunodeficient scid mice. Infect. Immun. 61:1641-1649.
259. Rudner XL, Happel KI, Young EA, Shellito JE. 2007. Interleukin-23 (IL-23)-IL-17 cytokine axis in murine Pneumocystis carinii infection. Infect. Immun. 75:3055-3061.
260. Ruebush TK, et al. 1978. An outbreak of Pneumocystis pneumonia in children with acute lymphocytic leukemia. Am. J. Dis. Child. 132:143-148.
261. Saijo S, et al. 2007. Dectin-1 is required for host defense against Pneumocystis carinii but not against Candida albicans. Nat. Immunol. 8:39-46.
262. Sattler FR, Cowan R, Nielsen DM, Ruskin J. 1988. Trimethoprim-sulfamethoxazole compared with pentamidine for treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective, noncrossover study. Ann. Intern. Med. 109:280-287.
263. Schmatz DM, et al. 1990. Treatment of Pneumocystis carinii pneumonia with 1,3-beta-glucan synthesis inhibitors. Proc. Natl. Acad. Sci. U. S. A. 87:5950-5954.
264. Sepkowitz KA, Brown AE, Armstrong D. 1995. Pneumocystis carinii pneumonia without acquired immunodeficiency syndrome. More patients, same risk. Arch. Intern. Med. 155:1125-1128.
265. Shelhamer JH, et al. 1984. Persistence of Pneumocystis carinii in lung tissue of acquired immunodeficiency syndrome patients treated for Pneumocystis pneumonia. Am. Rev. Respir. Dis. 130:1161-1165.
266. Shellito JE, Kolls JK, Olariu R, Beck JM. 1996. Nitric oxide and host defense against Pneumocystis carinii infection in a mouse model. J. Infect. Dis. 173:432-439.
267. Shellito JE, Tate C, Ruan S, Kolls J. 2000. Murine CD4+ T lymphocyte subsets and host defense against Pneumocystis carinii. J. Infect. Dis. 181:2011-2017.
268. Shipley TW, et al. 2010. Persistent Pneumocystis colonization leads to the development of chronic obstructive pulmonary disease in a nonhuman primate model of AIDS. J. Infect. Dis. 202:302-312.
269. Simonds RJ, Oxtoby MJ, Caldwell MB, Gwinn ML, Rogers MF. 1993. Pneumocystis carinii pneumonia among US children with perinatally acquired HIV infection. JAMA 270:470-473.
270. Sing A, Geiger AM, Hogardt M, Heesemann J. 2001. Pneumocystis carinii carriage among cystic fibrosis patients, as detected by nested PCR. J. Clin. Microbiol. 39:2717-2718.
271. Sing A, et al. 2009. Seasonal variation of Pneumocystis jirovecii infection: analysis of underlying climatic factors. Clin. Microbiol. Infect. 15:957-960.
272. Singer C, Armstrong D, Rosen PP, Schottenfeld D. 1975. Pneumocystis carinii pneumonia: a cluster of eleven cases. Ann. Intern. Med. 82:772-777.
273. Skelly M, et al. 2003. S-adenosylmethionine concentrations in diagnosis of Pneumocystis carinii pneumonia. Lancet 361:1267-1268.
274. Skelly MJ, Holzman RS, Merali S. 2008. S-adenosylmethionine levels in the diagnosis of Pneumocystis carinii pneumonia in patients with HIV infection. Clin. Infect. Dis. 46:467-471.
275. Spencer L, et al. 2008. Epidemiology of Pneumocystis colonization in families. Clin. Infect. Dis. 46:1237-1240.
276. Stansell JD, et al. 1997. Predictors of Pneumocystis carinii pneumonia in HIV-infected persons. Pulmonary Complications of HIV Infection Study Group. Am. J. Respir. Crit. Care Med. 155:60-66.
277. Steele C, et al. 2003. Alveolar macrophage-mediated killing of Pneumocystis carinii f. sp. muris involves molecular recognition by the dectin-1 β-glucan receptor. J. Exp. Med. 198:1677-1688.
278. Steele C, et al. 2002. Increased host resistance against Pneumocystis carinii pneumonia in gammadelta T-cell-deficient mice: protective role of gamma interferon and CD8(+) T cells. Infect. Immun. 70:5208-5215.
279. Stringer JR, Cushion MT. 1998. The genome of Pneumocystis carinii. FEMS Immunol. Med. Microbiol. 22:15-26.
280. Stringer JR, Keely SP. 2001. Genetics of surface antigen expression in Pneumocystis carinii. Infect. Immun. 69:627-639.
281. Stringer JR, Walzer PD. 1996. Molecular biology and epidemiology of Pneumocystis carinii infection in AIDS. AIDS 10:561-571.
282. Stringer SL, Hudson K, Blase MA, Walzer PD, Cushion MT, Stringer JR. 1989. Sequence from ribosomal RNA of Pneumocystis carinii compared to those of four fungi suggests an ascomycetous affinity. J. Protozool. 36:14S-16S.
283. Sunkin SM, Stringer JR. 1996. Translocation of surface antigen genes to a unique telomeric expression site in Pneumocystis carinii. Mol. Microbiol. 19:283-295.
284. Swain SD, Lee SJ, Nussenzweig MC, Harmsen AG. 2003. Absence of the macrophage mannose receptor in mice does not increase susceptibility to Pneumocystis carinii infection in vivo. Infect. Immun. 71:6213-6221.
285. Takahashi T, et al. 2002. Pneumocystis carinii carriage in immunocom-promised patients with and without human immunodeficiency virus infection. J. Med. Microbiol. 51:611-614.
286. Takeuchi T, et al. 2008. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann. Rheum. Dis. 67:189-194.
287. Thomas CF, Jr, Limper AH. 2004. Pneumocystis pneumonia. N. Engl. J. Med. 350:2487-2498.
288. Tipirneni R, et al. 2009. Healthcare worker occupation and immune response to Pneumocystis jirovecii. Emerg. Infect. Dis. 15:1590-1597.
289. Toma E, et al. 1998. Clindamycin with primaquine vs. trimethoprim-sulfamethoxazole therapy for mild and moderately severe Pneumocystis carinii pneumonia in patients with AIDS: a multicenter, double-blind, randomized trial (CTN 004). CTN-PCP Study Group. Clin. Infect. Dis. 27:524-530.
290. Totet A, et al. 2003. Immunocompetent infants as a human reservoir for Pneumocystis jirovecii: rapid screening by non-invasive sampling and real-time PCR at the mitochondrial large subunit rRNA gene. J. Eu-karyot. Microbiol. 50(Suppl):668-669.
291. Van der Meer MG, Brug SL. 1943. Infection a Pneumocystis chez l'homme et chez les animaux. Ann. Soc. Belg Med. Trop. 22:301-309.
292. Vanek J. 1951. Atypical (interstitial) pneumonia in children caused by Pneumocystis carinii. Cas Lek Cesk. 90:1121-1124.
293. Varela JM, et al. 2004. Climatic factors and Pneumocystis jiroveci infection in southern Spain. Clin. Microbiol. Infect. 10:770-772.
294. Varela JM, et al. 2003. Lymphocyte response in subjects with chronic pulmonary disease colonized by Pneumocystis jirovecii. J. Eukaryot. Microbiol. 50(Suppl):672-673.
295. Vargas SL, et al. 2001. Search for primary infection by Pneumocystis carinii in a cohort of normal, healthy infants. Clin. Infect. Dis. 32:855-861.
296. Vargas SL, Hughes WT, Wakefield AE, Oz HS. 1995. Limited persistence in and subsequent elimination of Pneumocystis carinii from the lungs after P. carinii pneumonia. J. Infect. Dis. 172:506-510.
297. Vargas SL, et al. 2010. Pneumocystis colonization in older adults and diagnostic yield ofsingle versus paired noninvasive respiratorysampling. Clin. Infect. Dis. 50:e19-e21.
298. Vargas SL, et al. 2007. Pneumocystis is not a direct cause of sudden infant death syndrome. Pediatr. Infect. Dis. J. 26:81-83.
299. Vargas SL, et al. 2000. Transmission of Pneumocystis carinii DNA from a patient with P. carinii pneumonia to immunocompetent contact health care workers. J. Clin. Microbiol. 38:1536-1538.
300. Vargas SL, et al. 2005. Detection of Pneumocystis carinii f. sp. hominis and viruses in presumably immunocompetent infants who died in the hospital or in the community. J. Infect. Dis. 191:122-126.
301. Vargas SL, et al. 2003. Pregnancy and asymptomatic carriage of Pneu-mocystis jiroveci. Emerg. Infect. Dis. 9:605-606.
302. Vassallo R, Kottom TJ, Standing JE, Limper AH. 2001. Vitronectin and fibronectin function as glucan binding proteins augmenting macrophage responses to Pneumocystis carinii. Am. J. Respir. Cell Mol. Biol. 25:203-211.
303. Vidal S, et al. 2006. Pneumocystis jirovecii colonisation in patients with interstitial lung disease. Clin. Microbiol. Infect. 12:231-235.
304. Vogel P, Miller CJ, Lowenstine LL, Lackner AA. 1993. Evidence of horizontal transmission of Pneumocystis carinii pneumonia in simian immunodeficiency virus-infected rhesus macaques. J. Infect. Dis. 168: 836-843.
305. Wada M, Sunkin SM, Stringer JR, Nakamura Y. 1995. Antigenic variation by positional control of major surface glycoprotein gene expression in Pneumocystis carinii. J. Infect. Dis. 171:1563-1568.
306. Wakefield AE. 1994. Detection of DNA sequences identical to Pneumocystis carinii in samples ofambient air. J. Eukaryot. Microbiol. 41:116S.
307. Wakefield AE. 1996. DNA sequences identical to Pneumocystis carinii f. sp. carinii and Pneumocystis carinii f. sp. hominis in samples ofair spora. J. Clin. Microbiol. 34:1754-1759.
308. Wakefield AE, Lindley AR, Ambrose HE, Denis CM, Miller RF. 2003. Limited asymptomatic carriage ofPneumocystis jiroveci in human immunodeficiency virus-infected patients. J. Infect. Dis. 187:901-908.
309. Wakefield AE, et al. 1990. Amplification of mitochondrial ribosomal RNA sequences from Pneumocystis carinii DNA ofrat and human origin. Mol. Biochem. Parasitol. 43:69-76.
310. Wakefield AE, et al. 1990. Detection of Pneumocystis carinii with DNA amplification. Lancet 336:451-453.
311. Wakefield AE, Stewart TJ, Moxon ER, Marsh K, Hopkin JM. 1990. Infection with Pneumocystis carinii is prevalent in healthy Gambian children. Trans. R. Soc. Trop. Med. Hyg. 84:800-802.
312. Walzer PD, et al. 2009. Long-term serologic responses to the Pneumocystis jirovecii major surface glycoprotein in HIV-positive individuals with and without P. jirovecii infection. J. Infect. Dis. 199:1335-1344.
313. Walzer PD, et al. 2008. Early predictors of mortality from Pneumocystis jirovecii pneumonia in HIV-infected patients: 1985-2006. Clin. Infect. Dis. 46:625-633.
314. Walzer PD, Rutledge ME. 1982. Serum antibody responses to Pneumo-cystis carinii among different strains ofnormal and athymic mice. Infect. Immun. 35:620-626.
315. Watanabe T, et al. 2009. Serum (1→3) β-D-glucan as a noninvasive adjunct marker for the diagnosis of Pneumocystis pneumonia in patients with AIDS. Clin. Infect. Dis. 49:1128-1131.
316. Wells J, Haidaris CG, Wright TW, Gigliotti F. 2006. Active immunization against Pneumocystis carinii with a recombinant P. carinii antigen. Infect. Immun. 74:2446-2448.
317. Weverling GJ, et al. 1999. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study Group. Lancet 353:1293-1298.
318. Wharton JM, et al. 1986. Trimethoprim-sulfamethoxazole or pentamidine for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective randomized trial. Ann. Intern. Med. 105:37-44.
319. Wilson JW, et al. 2011. Pneumocystis jirovecii testing by real-time poly-merase chain reaction and direct examination among immunocompe-tent and immunosuppressed patient groups and correlation to disease specificity. Diagn. Microbiol. Infect. Dis. 69:145-152.
320. Wissmann G, et al. 2011. Pneumocystis jirovecii colonization in patients treated with infliximab. Eur. J. Clin. Invest. 41:343-348.
321. Wissmann G, Varela JM, Calderon EJ. 2008. Prevention of Pneumocystis pneumonia in patients with inflammatory bowel disease based on the detection of Pneumocystis colonization. Inflamm. Bowel Dis. 14:17511752.
322. Wolff L, Horch S, Gemsa D. 1993. The development of Pneumocystis carinii pneumonia in germ-free rats requires immunosuppression and exposure to the Pneumocystis carinii organism. Comp. Immunol. Micro-biol. Infect. Dis. 16:73-76.
323. Wright TW, Gigliotti F, Harmsen A. 2005. Mechanisms of lung injury during Pneumocystis pneumonia, p. 327-348. In Walzer PD, Cushion MT (ed), Pneumocystis pneumonia, 3rd ed. Marcel Dekker, New York, NY.
324. Yale SH, Limper AH. 1996. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin. Proc. 71:5-13.
325. Yazaki H, et al. 2009. Outbreak of Pneumocystis jiroveci pneumonia in renal transplant recipients: P. jiroveci is contagious to the susceptible host. Transplantation 88:380-385.
326. Zhang C, et al. 2006. Toll-like receptor 2 mediates alveolar macrophage response to Pneumocystis murina. Infect. Immun. 74:1857-1864.
327. Zhang C, et al. 2006. Toll-like receptor 2 knockout reduces lung inflammation during Pneumocystis pneumonia but has no effect on phagocytosis of Pneumocystis organisms by alveolar macrophages. J. Eukaryot. Microbiol. 53(Suppl 1):S132-S133.
328. Zheng M, et al. 2005. CD4+ T cell-independent DNA vaccination against opportunistic infections. J. Clin. Invest. 115:3536-3544.